Introduction {#Sec1}
============

Initial hypoglycemic monotherapy is usually used in newly diagnosed type 2 diabetes patients, as currently recommended by the guidelines of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) \[[@CR1], [@CR2]\]. However, initial monotherapy is frequently insufficient to enable patients to achieve or sustain glycemic targets \[[@CR3], [@CR4]\]. Thus, initial combination therapy has emerged as an alternative approach. The latest position statement from the ADA/EASD \[[@CR2]\] called for an initial combination of two non-insulin agents in patients with a high baseline glycated hemoglobin (HbA1c) level (≥ 9.0%). Additionally, the latest American Association of Clinical Endocrinologists (AACE) treatment algorithm \[[@CR5]\] recommended that patients with a HbA1c level of \> 7.5% should receive combination therapy with metformin plus an additional drug.

However, we asked the question of whether initial combination therapy is actually more efficacious than monotherapy in terms of glucose control and confirmed safety. To search for the answer, we identified two published systematic reviews and meta-analyses. In one meta-analysis \[[@CR6]\] that included 15 randomized controlled trials (RCTs), the authors found that compared to metformin alone, combination therapy with metformin plus another anti-diabetes drug provided statistically significant reductions of 0.43% in HbA1c level and of 14.30 mg/dl in fasting plasma glucose (FPG) level. In another meta-analysis \[[@CR7]\] that included eight RCTs, the authors reported that compared with metformin monotherapy, initial combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors plus metformin was associated with a higher reduction of 0.49% in HbA1c level, a higher reduction of 0.80 mmol/l in FPG level and a lower weight loss of 0.44 kg. However, the authors of both of these meta-analyses did not present any further analysis with regard to the different types of hypoglycemic agent tested. Therefore, the aims of this study reported here were to comprehensively evaluate the efficacy and safety of initial combination therapies versus monotherapy using updated trial data in type 2 diabetes patients.

Methods {#Sec2}
=======

Literature Search {#Sec3}
-----------------

According to recommendations from the Cochrane Handbook for Systematic Reviews for meta-analysis, two independent investigators (XYG and WJY) conducted systematic searches of MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) for studies published between the date of inception and April 2017. The search terms were: "type 2 diabetes," "initial combination therapy," "early combination therapy," "treatment-naïve," "drug-naïve," "newly diagnosed diabetes" and "randomized controlled trials." Treatment-naïve or drug-naïve patients were defined as those patients diagnosed with type 2 diabetes who have not received treatment with any hypoglycemic agent. "Newly diagnosed diabetes patients" were defined as those patients diagnosed with type 2 diabetes for the first time and who had not received treatment. "Early combination studies" referred to the initial combination therapy for type 2 diabetes patients. This meta-analysis is registered as CRD42017060717 in PROSPERO (International Prospective Register of Systematic Reviews).

Study Selection and Data Extraction {#Sec4}
-----------------------------------

The inclusion criteria for this meta-analysis were: (1) studies of initial combination therapy with hypoglycemic agents compared with monotherapy; (2) efficacy of glucose control was the primary outcome of the study; (3) double-blind RCTs; (4) studies conducted with treatment-naïve type 2 diabetes patients. The exclusion criteria were: (1) studies conducted in type 1 diabetes patients; (2) the study was an extension study and not the original one; (3) study duration of \< 12 weeks.

Using the above inclusion and exclusion criteria, XYG and WJY independently evaluated the eligibility of all the studies identified in their search MEDLINE, Embase and CENTRAL. The Cochrane Collaboration tool \[[@CR8]\] was used to rate each RCT as having a low, high or unclear risk of bias from the following aspects: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, as well as other sources of bias (Electronic Supplementary Material \[ESM\] Table S1 and Fig. S1). WJY and XYG then extracted details from each article, including the publication data, study design, baseline characteristics, treatment arms, study duration, changes in glucose and weight control and the hypoglycemic rate. If several doses were used in one trial, the standard doses recommended and approved in the clinical practice were documented (ESM Table S2). The definition of drug-naïve patients and the percentage of drug-naïve patients in each treatment arm were also documented (ESM Table S3).

Statistical Analyses {#Sec5}
--------------------

The primary endpoint of this meta-analysis was the change in HbA1c level from baseline to the study endpoint in patients who received initial combination therapies compared with those receiving monotherapy. The secondary endpoints included changes in FPG, postprandial glucose (PPG) and body weight and the risk of hypoglycemia in patients who received initial combination therapies compared with those receiving monotherapy. Continuous outcomes were evaluated by computing the weighted mean differences (WMDs) and the 95% confidence intervals (CIs). Categorical outcomes were evaluated by computing the relative risks (RRs) and accompanying 95% CIs. Due to between-study heterogeneity, Higgins *I*^2^ statistics were used to evaluate the percentage of variance. Heterogeneity can be quantified as low, moderate and high, with upper limits of 25, 50 and 75% for *I*^2^, respectively \[[@CR9]--[@CR11]\]. The 95% CIs of *I*^2^ were also calculated \[[@CR11]\]. Publication bias was assessed using a funnel plot (ESM Fig. S2).

Meta-regression analysis was performed to evaluate whether the pre-specified covariates of baseline age, gender, HbA1c level and baseline body mass index (BMI) were associated with HbA1c changes from baseline corrected by monotherapy. Differences were considered to be statistically significant as *p* \< 0.05.

Statistical analyses were primarily performed using the Review Manager statistical software package (version 5.2; Nordic Cochrane Centre, Copenhagen, Denmark). Analyses were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for conducting and reporting meta-analyses of RCTs \[[@CR12]\]. Meta-regression analyses were performed using the STATA statistical software package (version 11.0; StataCorp, College Station, TX, USA).

This article does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec6}
=======

Characteristics and Methodological Quality of Included Studies {#Sec7}
--------------------------------------------------------------

A total of 36 studies were included in the meta-analysis (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). Of these, 12 were studies \[[@CR13]--[@CR24]\] with initial combination therapies of DPP-4 inhibitors plus metformin, three were studies \[[@CR25]--[@CR27]\] in which the initial combination therapy was sulfonylurea (SU) or glinide plus metformin, four were studies \[[@CR28]--[@CR31]\] in which the initial combination therapy was thiazolidinedione (TZD) plus metformin, three were studies \[[@CR32]--[@CR34]\] in which the initial combination therapy was sodium glucose cotransporter 2 (SGLT2) inhibitor plus metformin and six studies \[[@CR35]--[@CR40]\] utilized an initial combination therapy of DPP-4 inhibitor plus TZD. There were also eight trials with other initial combination therapies \[[@CR41]--[@CR48]\].Fig. 1Flow chart of included studies.*DDT-4* Dipeptidyl peptidase-4,*SGLT2* sodium glucose cotransporter 2,*SU* sulfonylurea,*TZD* thiazolidinedione Table 1Characteristics of randomized controlled trials in initial combination therapy in type 2 diabetesFirst author, yearStudy durationTreatment groupsNo. of patientsAge (years)Male (%)Body mass index (kg/m^2^)Duration of diabetes mellitus (years)Baseline glycated hemoglobin (HbA1c) (%)Baseline weight (kg)DPP-4 inhibitors + metformin initial combination therapy vs. metformin monotherapy Goldstein, 2007 \[[@CR13]\]24 weeksSitagliptin 50 mg + metformin 1000 mg bid18253.3 ± 9.642.332.4 ± 6.64.4 ± 4.28.7 ± 0.9--Metformin 1000 mg bid18253.2 ± 9.645.132.2 ± 7.14.4 ± 4.48.7 ± 0.9-- Goldstein, 2007-2 \[[@CR13]\]24 weeksSitagliptin 50 mg + metformin 500 mg bid19054.1 ± 10.055.332.1 ± 6.74.5 ± 4.78.8 ± 1.0--Metformmin 500 mg bid18253.2 ± 10.248.932.1 ± 6.84.5 ± 3.98.9 ± 1.0-- Bosi, 2009 \[[@CR14]\]24 weeksVildagliptin 50 mg + metformin 1000 mg bid29552.8 ± 10.645831.37 ± 4.751.87 ± 2.608.70 ± 1.0389.79 ± 18.87Metformin 1000 mg bid29452.4 ± 10.7158.231.31 ± 4.582.19 ± 3.338.62 ± 0.9388.43 ± 17.39 Jadzinsky, 2009 \[[@CR15]\]24 weeksSaxagliptin 10 mg + metformin32352.1 ± 11.645.230.3 ± 5.01.4 ± 2.59.5 ± 1.282.5 ± 16.9Metformin32851.8 ± 10.749.730.2 ± 4.91.7 ± 3.19.4 ± 1.382.8 ± 17.5 Reasner, 2011 \[[@CR16]\]18 weeksSitagliptin/metformin FDC62549.4 ± 10.55632.9 ± 7.23.5 ± 4.59.9 ± 1.894.7 ± 23.4Metformmin62150.0 ± 10.55733.7 ± 7.83.2 ± 4.39.8 ± 1.897.2 ± 25.5 Haak, 2012 \[[@CR17]\]24 weeksLinagliptin 2.5 mg + metformin 1000 mg bid14356.4 ± 10.753.828.6 ± 4.8--8.7 ± 1.076.7 ± 16.0Metformin 1000 mg bid14755.2 ± 10.653.129.5 ± 5.3--8.5 ± 0.980.0 ± 18.5 Haak, 2012-2 \[[@CR17]\]24 weeksLinagliptin 2.5 mg + metformin 500 mg bid14355.6 ± 11.251.029.7 ± 5.3--8.7 ± 1.080.8 ± 19.0Metformin 500 mg bid14452.9 ± 10.456.928.9 ± 4.8--8.7 ± 0.979.9 ± 18.4 Pratley, 2014 \[[@CR18]\]26 weeksAlogliptin/metformin 12.5/1000 mg bid11454.6 ± 10.4254.431.0 ± 5.384.2 ± 4.97----Metformin 1000 mg bid11152.6 ± 11.3045.930.5 ± 5.04.1 ± 4.59---- Pratley, 2014-2 \[[@CR18]\]26 weeksAlogliptin/metformin 12.5/500 mg bid11153.7 ± 11.5943.230.9 ± 5.354.1 ± 4.78----Metformin 500 mg bid11454.6 ± 10.2041.230.2 ± 4.843.8 ± 3.90---- Ji, 2015 \[[@CR19]\]24 weeksLinagliptin 5 mg + metformin 1000 mg34453.1 ± 10.749.129 ± 5.7--8 ± 1.076.7 ± 18.8Metformin 2000 mg34552.9 ± 10.745.829 ± 5.6--8 ± 0.876.0 ± 18.8 Ji, 2016 \[[@CR20]\]24 weeksSitagliptin 50 mg/metformin 850 mg bid12552.4 ± 9.353.625.4 ± 3.11.1 ± 0.38.6 ± 0.969.4 ± 10.8Metformin 850 mg bid12453.0 ± 10.360.525.8 ± 3.51.1 ± 0.28.7 ± 1.171.1 ± 11.8Ji, 2016-2 \[[@CR20]\]24 weeksSitagliptin 50 mg/metformin 500 mg bid12252.6 ± 11.369.726.1 ± 3.41.1 ± 0.38.5 ± 1.072.4 ± 12.1Metformin 500 mg bid12652.6 ± 9.554.826.0 ± 3.71.0 ± 0.28.7 ± 1.071.1 ± 13.7 Mu, 2016 \[[@CR21]\]24 weeksLinagliptin 2.5 mg/metformin 1000 mg bid14750.7 ± 9.459.226.0 ± 3.7--8.7 ± 1.070.5 ± 12Metformin 1000 mg bid14451.4 ± 10.463.226.1 ± 3.3--8.6 ± 1.071.0 ± 12 Mu, 2016-2 \[[@CR21]\]24 weeksLinagliptin 2.5 mg/metformin 500 mg bid14751.4 ± 10.262.626.0 ± 3.6--8.7 ± 0.970.8 ± 12Metformin 500 mg bid14552.1 ± 9.662.825.8 ± 3.3--8.7 ± 1.169.1 ± 10.7 Dou, 2017 \[[@CR22]\]24 weeksSaxagliptin 5 mg + metformin 500 mg21050.8 ± 10.464.826.7 ± 3.70.97 ± 2.19.4 ± 1.1--Metformin 500 mg + placebo20750.1 ± 11.063.826.5 ± 3.60.72 ± 2.19.5 ± 1.0-- JI, 2017 \[[@CR23]\]26 weeksAlogliptin 12.5 mg + metformin 500 mg FDC bid15953.4 ± 10.4657.226.16 ± 3.51--8.39 ± 0.81--Metformin 500 mg bid16253.6 ± 9.9150.626.30 ± 3.57--8.40 ± 0.78--DPP-4 inhibitors + metformin initial combination therapy vs. DPP-4 inhibitor monotherapy Goldstein, 2007 \[[@CR13]\]24 weeksSitagliptin 50 mg + metformin 1000 mg bid18253.3 ± 9.642.332.4 ± 6.64.4 ± 4.28.7 ± 0.9--Sitagliptin 100 mg qd17953.3 ± 10.252.031.2 ± 5.94.4 ± 4.68.9 ± 1.0-- Bosi, 2009 \[[@CR14]\]24 weeksVildagliptin 50 mg + metformin 1000 mg bid29552.8 ± 10.645831.37 ± 4.751.87 ± 2.608.70 ± 1.0389.79 ± 18.87Vildagliptin 50 mg bid30053.5 ± 10.956031.26 ± 4.822.12 ± 3.328.68 ± 1.0287.84 ± 17.93 Jadzinsky, 2009 \[[@CR15]\]24 weeksSaxagliptin 10 mg + metformin32352.1 ± 11.645.230.3 ± 5.01.4 ± 2.59.5 ± 1.282.5 ± 16.9Saxagliptin 10 mg33552.1 ± 10.250.430.2 ± 4.91.7 ± 2.89.6 ± 1.383.1 ± 16.9 Haak, 2012 \[[@CR17]\]24 weeksLinagliptin 2.5 mg + metformin 1000 mg bid14356.4 ± 10.753.828.6 ± 4.8--8.7 ± 1.076.7 ± 16.0Linagliptin 5 mg qd14256.2 ± 10.856.329.0 ± 4.7--8.7 ± 1.079.1 ± 17.3 Pratley, 2014 \[[@CR18]\]26 weeksAlogliptin/metformin 12.5/1000 mg bid11454.6 ± 10.4254.431.0 ± 5.384.2 ± 4.97----Alogliptin 25 mg qd11252.6 ± 9.3842.930.8 ± 5.223.6 ± 4.12---- Ross, 2015 \[[@CR24]\]24 weeksLinagliptin 5 mg + metformin15949 ± 10.943.429.84 ± 5.82--9.79 ± 1.19--Linagliptin 5 mg15748.6 ± 11.24929.63 ± 5.43--9.88 ± 1.10-- Ji, 2016 \[[@CR20]\]24 weeksSitagliptin 50 mg/metformin 850 mg bid12552.4 ± 9.353.625.4 ± 3.11.1 ± 0.38.6 ± 0.969.4 ± 10.8Sitagliptin 50 mg bid12051.7 ± 10.261.726.0 ± 3.51.1 ± 0.28.7 ± 1.171.8 ± 12.1 Mu, 2016 \[[@CR21]\]24 weeksLinagliptin 2.5 mg/metformin 1000 mg bid14750.7 ± 9.459.226.0 ± 3.7--8.7 ± 1.070.5 ± 12Linagliptin 5 mg qd14750.8 ± 10.551.726.2 ± 3.9--8.7 ± 0.970.2 ± 13.5 Dou, 2017 \[[@CR22]\]24 weeksSaxagliptin 5 mg + metformin 500 mg21050.8 ± 10.464.826.7 ± 3.70.97 ± 2.19.4 ± 1.1--Saxagliptin 5 mg + placebo21349.5 ± 10.970.926.5 ± 3.20.73 ± 1.69.4 ± 1.0-- JI, 2017 \[[@CR23]\]26 weeksAlogliptin 12.5 mg + metformin 500 mg FDC bid15953.4 ± 10.4657.226.16 ± 3.51--8.39 ± 0.81--Alogliptin 12.5 mg bid16355.4 ± 9.6260.126.16 ± 3.92--8.48 ± 0.71--SU + metformin initial combination therapy vs. metformin monotherapy Garber, 2002 \[[@CR25]\]20 weeksGlyburide/metformin 2.5/500 mg16558.1 ± 9.858.229.6 ± 4.53.30 ± 3.188.18 ± 1.1486.7 ± 17.5Metformin 500 mg16156.0 ± 11.057.830.4 ± 4.32.98 ± 2.748.26 ± 1.0888.6 ± 14.9 Garber, 2003 \[[@CR26]\]16 weeksGlyburide/metformin 1.25/500 mg17155.6 ± 11.244.431.4 ± 4.63.0 ± 3.08.8 ± 1.591.9 ± 17.4Metformin 500 mg16454.7 ± 11.843.331.4 ± 4.02.6 ± 2.38.5 ± 1.492.8 ± 15.6 Horton, 2004 \[[@CR27]\]24 weeksNateglinide 120 mg + metformin 500 mg tid8957.7 ± 1.265.230.6 ± 0.43.4 ± 0.48.2 ± 0.1--Metformin 500 mg tid10455.4 ± 1.167.329.9 ± 0.43.7 ± 0.48.3 ± 0.1--SU/glinide + metformin initial combination therapy vs. SU/glinide monotherapy Garber, 2002 \[[@CR25]\]20 weeksGlyburide/metformin 2.5/500 mg16558.1 ± 9.858.229.6 ± 4.53.30 ± 3.188.18 ± 1.1486.7 ± 17.5Glyburide 2.5 mg16156.5 ± 10.550.930.3 ± 3.92.81 ± 3.148.21 ± 1.0987.2 ± 15.3 Garber, 2003 \[[@CR26]\]16 weeksGlyburide/metformin 1.25/500 mg17155.6 ± 11.244.431.4 ± 4.63.0 ± 3.08.8 ± 1.591.9 ± 17.4Glyburide 2.5 mg15155.3 ± 12.243.731.1 ± 4.33.0 ± 2.68.7 ± 1.491.0 ± 16.0 Horton, 2004 \[[@CR27]\]24 weeksNateglinide 120 mg +Metformin 500 mg tid8957.7 ± 1.265.230.6 ± 0.43.4 ± 0.48.2 ± 0.1--Nateglinide 120 mg10457.9 ± 1.056.729.9 ± 0.44.7 ± 0.68.1 ± 0.1--TZD + metformin initial combination therapy vs. metformin monotherapy Rosenstock, 2006 \[[@CR28]\]32 weeksRosiglitazone/Metformmin15550.1 ± 10.75733.2 ± 7.72.3 ± 2.78.9 ± 1.1--Metformin15451.5 ± 10.45632.5 ± 7.02.9 ± 3.78.8 ± 1.0-- Stewart, 2006 \[[@CR29]\]32 weeksRoziglitazone + metformin25458.9 ± 8.45530.9 ± 5.43.7 ± 3.67.2 ± 0.688.1 ± 16.3metformin27259.0 ± 7.95630.6 ± 5.53.7 ± 3.67.2 ± 0.687.2 ± 16.5 Perez, 2009 \[[@CR30]\]24 weeksPioglitazone 15 mg + metformin 850 mg bid20154.7 ± 12.244.830.8 ± 5.7--8.89 ± 0.07--Metformin 850 mg bid21053.7 ± 12.046.730.8 ± 5.7--8.65 ± 0.07-- Borges, 2011 \[[@CR31]\]80 weeksRosiglitazone/metformin34451.5 ± 10.55332.2 ± 6.82.3 ± 3.18.6 ± 0.987.1 ± 21.3Metformin33450.7 ± 10.55333.1 ± 7.12.6 ± 3.38.6 ± 0.990.6 ± 22.8TZD + metformin initial combination therapy vs. TZD monotherapy Rosenstock, 2006 \[[@CR28]\]32 weeksRosiglitazone/Metformmin15550.1 ± 10.75733.2 ± 7.72.3 ± 2.78.9 ± 1.1--Rosiglitazone15950.6 ± 10.25832.8 ± 7.12.7 ± 3.08.8 ± 1.0-- Perez, 2009 \[[@CR30]\]24 weeksPioglitazone 15 mg + metformin 850 mg bid20154.7 ± 12.244.830.8 ± 5.7--8.89 ± 0.07--Pioglitazone 15 mg bid18954.0 ± 12.134.931.2 ± 5.5--8.69 ± 0.07--SGLT2 inhibitors + metformin initial combination therapy vs. metformin monotherapy Henry, 2012--2 \[[@CR32]\]24 weeksDapagliflozin 10 mg + metformin 2000 mg21151.0 ± 10.150.2--2.2 ± 3.39.1 ± 1.388.4 ± 19.7Metformin 2000 mg + placebo20852.7 ± 10.446.6--1.9 ± 4.09.1 ± 1.387.2 ± 19.4 Hadjadj, 2016 \[[@CR33]\]24 weeksEmpagliflozin 25 mg + metformin 2000 mg16953.6 ± 10.752.130.4 ± 5.3--8.66 ± 1.1483.8 ± 19.8Metformin 2000 mg16451.6 ± 10.856.130.5 ± 5.9--8.58 ± 1.1383.7 ± 20.1 Rosenstock, 2016 \[[@CR34]\]26 weeksCanagliflozin 300/Metformin 2000 mg23755.4 ± 9.848.532.8 ± 6.53.3 ± 3.98.9 ± 1.291.4 ± 21.4Metformin 2000 mg23755.2 ± 9.848.933.0 ± 6.03.3 ± 4.58.8 ± 1.292.1 ± 20.1SGLT2 inhibitors + metformin initial combination therapy vs. SGLT2 inhibitor monotherapy Henry, 2012--1 \[[@CR32]\]24 weeksDapagliflozin 5 mg + metformin19451.7 ± 9.340.2--1.6 ± 2.49.2 ± 1.384.1 ± 19.5Dapagliflozin 5 mg + placebo20352.3 ± 10.245.3--1.6 ± 3.19.1 ± 1.486.2 ± 21.1 Henry, 2012--2 \[[@CR32]\]24 weeksDapagliflozin 10 mg + metformin21151.0 ± 10.150.2--2.2 ± 3.39.1 ± 1.388.4 ± 19.7Dapaglifozin 10 mg + placebo21951.1 ± 11.547.9--2.1 ± 3.89.1 ± 1.388.5 ± 19.3 Hadjadj, 2016 \[[@CR33]\]24 weeksEmpagliflozin 25 mg + metformin 2000 mg16953.6 ± 10.752.130.4 ± 5.3--8.66 ± 1.1483.8 ± 19.8Empagliflozin 25 mg16453.3 ± 10.750.630.6 ± 5.9--8.86 ± 1.2983.1 ± 20.3 Hadjadj, 2016-2 \[[@CR33]\]24 weeksEmpagliflozin 10 mg + metformin 2000 mg16752.3 ± 11.359.330.5 ± 5.0--8.65 ± 1.2383.0 ± 19.1Empagliflozin 10 mg16953.1 ± 10.757.430.3 ± 5.2--8.62 ± 1.2483.8 ± 19.8 Rosenstock, 2016 \[[@CR34]\]26 weeksCanagliflozin 100 mg/Metformin23754.2 ± 9.645.631.9 ± 5.32.9 ± 3.38.8 ± 1.188.3 ± 17.6Canagliflozin 100 mg23754.0 ± 10.744.332.4 ± 5.43.5 ± 4.48.8 ± 1.290.2 ± 18.6 Rosenstock, 2016-2 \[[@CR34]\]26 weeksCanagliflozin 300/Metformin23755.4 ± 9.848.532.8 ± 6.53.3 ± 3.98.9 ± 1.291.4 ± 21.4Canagliflozin 300 mg23855.8 ± 9.652.532.6 ± 5.83.3 ± 4.48.8 ± 1.293.0 ± 19.9DPP-4 inhibitors + TZD initial combination therapy vs. TZD monotherapy Rosenstock, 2007 \[[@CR35]\]24 weeksVildagliptin + piogglitazone 100/30 mg qd14851.0 ± 11.358.129.6 ± 5.82.0 ± 3.18.8 ± 1.1--Piogglitazone 30 mg qd16152.4 ± 10.364.028.9 ± 5.52.2 ± 3.38.7 ± 1.0-- Rosenstock, 2010 \[[@CR36]\]26 weeksAlogliptin 25 mg + piogglitazone 30 mg164--------8.80 ± 0.962--Pioglitazone 30 mg163--------8.76 ± 1.005-- Yoon, 2011 \[[@CR37]\]24 weeksSitagliptin 100 mg + piogglitazone 30 mg26150.2 ± 10.252.529.7 ± 5.12.6 ± 4.39.5 ± 1.280.1 ± 17.4Piogglitazone 30 mg25951.7 ± 11.256.029.6 ± 5.22.1 ± 3.99.5 ± 1.280.4 ± 17.8 Yoon, 2012 \[[@CR38]\]54 weeksSitagliptin 100 mg + piogglitazone 45 mg16451.4 ± 10.052.429.7 ± 4.82.6 ± 4.09.4 ± 1.181.6 ± 17.4Piogglitazone 45 mg15352.3 ± 11.558.829.9 ± 5.31.6 ± 3.79.4 ± 1.481.9 ± 18.4 Gomis, 2011 \[[@CR39]\]24 weeksLinagliptin 5 mg + pioglitazone 30 mg25957.7 ± 9.658.728.7 ± 4.8--8.60 ± 0.7978.3 ± 15.6Pioglitazone 30 mg + placebo13057.1 ± 10.165.429.7 ± 4.8--8.58 ± 0.8782.7 ± 15.8 Henry, 2014 \[[@CR40]\]54 weeksSitagliptin 100 mg + pioglitazone 15 mg19352.650.830.7 ± 5.44.1 ± 48.9 ± 1.2--Pioglitazone 15 mg18350.36530.7 ± 5.23.7 ± 4.28.9 ± 1.0-- Henry, 2014--2 \[[@CR40]\]54 weeksSitagliptin 100 mg + pioglitazone 30 mg19051.158.931.1 ± 5.83.8 ± 3.88.7 ± 1.1--Pioglitazone 30 mg19451.854.130.9 ± 5.63.9 ± 4.08.9 ± 1.1-- Henry, 2014--3 \[[@CR40]\]54 weeksSitagliptin 100 mg + pioglitazone 45 mg19853.559.630.5 ± 4.94.0 ± 4.58.9 ± 1.1--Pioglitazone 45 mg18852.550.531.2 ± 5.13.7 ± 4.08.8 ± 1.1--DPP-4 inhibitors + TZD initial combination therapy vs. DPP-4 inhibitor monotherapy Henry, 2014 \[[@CR40]\]54 weeksSitagliptin 100 mg + pio 30 mg19051.158.931.1 ± 5.83.8 ± 3.88.7 ± 1.1--Sitagliptin 100 mg1865160.231.4 ± 5.74.5 ± 6.88.7 ± 1.2-- Rosenstock, 2007 \[[@CR35]\]24 weeksVildagliptin + piog 100/30 mg qd14851.0 ± 11.358.129.6 ± 5.82.0 ± 3.18.8 ± 1.1--Vildagliptin 100 mg qd15451.4 ± 10.863.629.4 ± 5.81.9 ± 3.18.6 ± 1.0-- Rosenstock, 2010 \[[@CR36]\]26 weeksAlogliptin 25 mg + piogglitazone 30 mg164--------8.80 ± 0.962--Alogliptin 25 mg164--------8.80 ± 0.988--SU/glinide + AGI initial combination therapy vs. AGI monotherapy Tatsumi, 2013 \[[@CR41]\]12 weeksMiglitol + mitiglinide2163.4 ± 8.947.624.8 ± 0.97.6 ± 5.57.19 ± 0.5062.2 ± 2.9Miglitol2262.9 ± 11.468.224.9 ± 1.27.3 ± 9.37.09 ± 0.8267.7 ± 3.4SU/glinide + AGI initial combination therapy vs. SU/glinide monotherapy Tatsumi, 2013 \[[@CR41]\]12 weeksMiglitol + mitiglinide2163.4 ± 8.947.624.8 ± 0.97.6 ± 5.57.19 ± 0.5062.2 ± 2.9Mitiglinide2165.4 ± 10.442.925.2 ± 0.86.1 ± 6.27.10 ± 0.4862.7 ± 2.5SU/glinide + TZD initial combination therapy vs. TZD monotherapy Chou, 2008 \[[@CR42]\]28 weeksRosiglitazone + glimepiride (8 mg/4 mg)21854.9 ± 11.659.631.8 ± 6.22.0 ± 0.309.2 ± 1.390.2 ± 19.7Rosiglitazone23053.6 ± 10.760.031.3 ± 5.82.0 ± 0.219.1 ± 1.388.9 ± 19.8SU/glinide + TZD initial combination therapy vs. SU/glinide monotherapy Chou, 2008 \[[@CR42]\]28 weeksRosiglitazone + glimepiride (8 mg/4 mg)21854.9 ± 11.659.631.8 ± 6.22.0 ± 0.309.2 ± 1.390.2 ± 19.7Glimepiride22253.0 ± 11.057.731.8 ± 7.21.0 ± 0.189.0 ± 1.391.6 ± 23.6DPP-4 inhibitors + metformin initial combination therapy vs. TZD monotherapy Wainstein, 2012 \[[@CR43]\]32 weeksSitagliptin + metformin26152.4 ± 10.754.830.0 ± 6.13.2 ± 4.09.0 ± 1.382.8 ± 21.1Pioglitazone25652.2 ± 11.052.329.6 ± 5.53.3 ± 3.58.9 ± 1.381.4 ± 19.9DPP-4 inhibitors + metformin initial combination therapy vs SU monotherapy Amblee, 2016 \[[@CR44]\]12 weeksSaxagliptin + metformin FDC5045.6 ± 7.38034.3 ± 11.3--10.9 ± 1.4--Glipizide5043.2 ± 10.68234.3 ± 5.8--11.1 ± 1.39--Colesvelam + metformin initial combination therapy vs. metformin monotherapy Rosenstock, 2010 \[[@CR45]\]16 weeksColesvelam + metformin14552.7 ± 11.54830.6 ± 4.7--7.8 ± 1.080.8 ± 15.5Metformin14153.9 ± 10.14029.8 ± 4.4--7.5 ± 0.977.3 ± 16.2DPP-4 inhibitors + AGI initial combination therapy vs AGI monotherapy Mikada, 2014 \[[@CR46]\]24 weeksMiglitol + sitagliptin1360.5 ± 11.553.828.3 ± 2.57.4 ± 3.17.14 ± 0.7673.8 ± 10.2Miglitol1458.7 ± 7.078.629.5 ± 5.59.3 ± 5.86.90 ± 0.5181.4 ± 11.2DPP-4 inhibitors + AGI initial combination therapy vs. DPP-4 inhibitor monotherapy Mikada, 2014 \[[@CR46]\]24 weeksMiglitol + sitagliptin1360.5 ± 11.553.828.3 ± 2.57.4 ± 3.17.14 ± 0.7673.8 ± 10.2Sitagliptin1459.2 ± 11.878.628.8 ± 2.57.6 ± 8.07.45 ± 0.9376.8 ± 11.4SGLT2 inhibitors + DPP-4 inhibitors initial combination therapy vs SGLT2 inhibitor monotherapy Lewin 2015 \[[@CR47]\]24 weeksEmpagliflozin 25 mg + linagliptin 5 mg13454.2 ± 10.052.231.8 ± 5.3--7.99 ± 0.9587.9 ± 18.2Empagliflozin 25 mg13356.0 ± 9.357.931.2 ± 5.7--7.99 ± 0.9786.7 ± 19.7SGLT2 inhibitors + DPP-4 inhibitors initial combination therapy vs. DPP-4 inhibitor monotherapy Lewin 2015 \[[@CR47]\]24 weeksEmpagliflozin 25 mg + linagliptin 5 mg13454.2 ± 10.052.231.8 ± 5.3--7.99 ± 0.9587.9 ± 18.2Linagliptin 5 mg13353.8 ± 11.556.431.9 ± 5.9--8.05 ± 0.8989.5 ± 20.1Triple initial combination therapy vs. conventional therapy Abdul-Ghani, 2015 \[[@CR48]\]24 monthsMetformin + pioglitazone + exenatide7947 ± 15536.4 ± 10.42 ± 0.068.6 ± 0.2101.6 ± 2.3Conventional therapy9146 ± 16236.6 ± 10.42 ± 0.058.6 ± 0.2101.0 ± 3.4*AGI* Alpha-glucosidase inhibitor,*bid* twice daily, *DDT-4* Dipeptidyl peptidase-4,*FDC* fixed-dose combination,*qd* once daily,*SGLT2* sodium glucose cotransporter 2,*SU* sulfonylurea,*tid* three times daily*TZD* thiazolidinedione

Our meta-analysis included studies that were randomized, placebo-controlled, with double-blind treatment. The eligibility criteria were clearly reported in all of the trials. Most studies reported baseline age, BMI, HbA1c level and duration of diabetes between the comparison groups. The risk of bias as evaluated by the Cochrane instrument was low (ESM Fig. S1). The visual inspection of the funnel plots indicated low risks of publication bias (ESM Fig. S2). For some treatment groups included only one trial, no further meta-analysis was done in each group \[[@CR41]--[@CR48]\]. Those extension studies were excluded from this meta-analysis.

Efficacy of Initial Combination Therapy {#Sec8}
---------------------------------------

Compared with metformin monotherapy, initial combinations of DPP-4 inhibitors and metformin exhibited significant decreases in HbA1c (WMD, − 0.44%, *p* \< 0.001), FPG (WMD, − 0.77 mmol/l, *p* \< 0.001) and PPG (WMD, − 1.65 mmol/l, *p* \< 0.001), but increased body weight significantly (WMD, 0.38 kg, *p* \< 0.001). Compared with DPP-4 inhibitors monotherapy, initial combinations of DPP-4 inhibitors and metformin caused significant decreases in HbA1c (WMD, − 0.88%, *p* \< 0.001), FPG (WMD, − 1.61 mmol/l, *p* \< 0.001), PPG (WMD, − 2.69 mmol/l, *p* \< 0.001) and body weight (WMD, − 1.00 kg, *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}; Figure S3).Table 2Comparisons of initial combination therapy versus monotherapy in terms of glycemic control and change in body weightComparison groupIncluded studiesNo. of patientsWMD95% CI*p* value*I*^2^ (%)95% CI of *I*^2^DPP-4 inhibitors +  metformin vs. DPP-4 inhibitors HbA1c (%)101967/1951− 0.88− 0.99, − 0.78\< 0.0011000.76, 1.24 FPG (mmol/l)91824/1823− 1.61− 1.84, − 1.37\< 0.0011000.75, 1.25 PPG (mmol/l)61065/1020− 2.69− 3.27, − 2.12\< 0.0011000.65, 1.35 Weight (kg)81627/1624− 1.00− 1.28, − 0.77\< 0.0011000.73, 1.27DPP-4 inhibitors + metformin vs. metformin HbA1c (%)113379/3375− 0.44− 0.57, − 0.31\< 0.0011000.81, 1.19 FPG (mmol/l)103085/3086− 0.77− 1.02, − 0.51\< 0.0011000.80, 1.20 PPG (mmol/l)51377/1374− 1.65− 2.09, − 1.21\< 0.001990.70, 1.28 Weight (kg)82505/25050.380.22, 0.54\< 0.001990.77, 1.21SU/glinide + metformin vs. metformin HbA1c (%)3425/429− 0.68− 0.86, − 0.50\< 0.0011000.32, 1.68 FPG (mmol/l)3425/429− 0.87− 1.38, − 0.36\< 0.0011000.32, 1.68 PPG (mmol/l)3425/429− 0.70− 1.02, − 0.38\< 0.001990.31, 1.67 Weight (kg)2336/3252.602.40, 2.80\< 0.00195--SU/glinide + metformin vs. SU/glinide HbA1c (%)3425/416− 0.49− 0.77, − 0.20\< 0.0011000.32, 1.68 FPG (mmol/l)3425/416− 0.66− 1.12, − 0.200.0051000.32, 1.68 PPG (mmol/l)3425/416− 0.87− 1.29, − 0.46\< 0.0011000.32, 1.68 Weight (kg)2336/312− 0.10− 0.69, 0.490.7499--TZD + metformin vs. metformin HbA1c (%)4954/970− 0.44− 0.68, − 0.19\< 0.001990.50, 1.48 FPG (mmol/l)4954/970− 0.88− 1.20, − 0.55\< 0.0011000.51, 1.49 PPG (mmol/l)-------------- Weight (kg)4954/9701.931.88, 1.97\< 0.00140− 0.09, 0.89TZD + metformin vs. TZD HbA1c (%)2356/348− 0.83− 0.97, − 0.68\< 0.00141-- FPG (mmol/l)2356/348− 1.25− 1.75, − 0.75\< 0.00199-- PPG (mmol/l)-------------- Weight (kg)2356/348− 1.22− 1.89, − 0.55\< 0.00176--SGLT2 inhibitors +  metformin vs. metformin HbA1c (%)3978/974− 0.47− 0.58, − 0.37\< 0.001980.30, 1.66 FPG (mmol/l)2642/646− 1.38− 1.60, − 1.17\< 0.00199-- PPG (mmol/l)-------------- Weight (kg)3978/974− 2.00− 2.29, − 1.71\< 0.001980.30, 1.66SGLT2 inhibitors + metformin vs, SGLT2 inhibitors HbA1c (%)3978/989− 0.64− 0.84, − 0.43\< 0.0011000.32, 1.68 FPG (mmol/l)2642/646− 0.83− 1.05, − 0.61\< 0.00199-- PPG (mmol/l)-------------- Weight (kg)3978/989− 0.66− 1.06, − 0.27\< 0.001990.31, 1.67DPP-4 inhibitors + TZD vs. TZD HbA1c (%)61577/1431− 0.54− 0.65, − 0.44\< 0.001990.70, 1.28 FPG (mmol/l)61577/1431− 0.89− 1.01, − 0.76\< 0.001970.68, 1.26 PPG (mmol/l)4842/824− 1.97− 2.37, − 1.58\< 0.001970.48, 1.46 Weight (kg)61577/14310.960.79, 1.14\< 0.001960.67, 1.25DPP-4 inhibitors + TZD vs. DPP-4 inhibitors HbA1c (%)3502/504− 0.62− 0.75, − 0.48\< 0.001990.31, 1.67* I*^2^ (mmol/l)3502/504− 1.41− 1.50, − 1.31\< 0.001900.22, 1.58 PPG (mmol/l)-------------- Weight (kg)3502/5043.512.13, 4.88\< 0.0011000.32, 1.68*CI*Confidence interval, *FPG* fasting plasma glucose,*HbA1c* glycated hemoglobin, *PPG* postprandial plasma glucose, *I*^2^ Higgins *I*^2^ statistics, *WMD* weighted mean difference

Compared with metformin monotherapy, initial treatment combinations of SU/glinides plus metformin resulted in significant decreases in the levels of HbA1c (WMD − 0.68%; *p* \< 0.001), FPG (WMD,− 0.87 mmol/l; *p* \< 0.001) and PPG (WMD − 0.70 mmol/l; *p* \< 0.001), but significant increases in body weight (WMD 2.60 kg; *p* \< 0.001). Compared with SU/glinide monotherapy, initial combinations of SU/glinides plus metformin exhibited significant decreases in the levels of HbA1c (WMD − 0.49%; *p* \< 0.001), FPG (WMD − 0.66 mmol/l; *p* = 0.005) and PPG (WMD − 0.87 mmol/l; *p* \< 0.001) and similar changes in weight (WMD − 0.10 kg; *p* = 0.74) (Table [2](#Tab2){ref-type="table"}; ESM Fig. S3).

Compared with metformin monotherapy, initial combinations of TZDs plus metformin led to significant decreases in HbA1c (WMD − 0.44%; *p* \< 0.001) and FPG levels (WMD, − 0.88 mmol/l; *p* \< 0.001) but increased body weight significantly (WMD 1.93 kg; *p* \< 0.001). Compared with TZD monotherapy, initial combinations of TZDs plus metformin led to significant decreases in the levels of HbA1c (WMD − 0.83%; *p* \< 0.001) and FPG (WMD − 1.25 mmol/l; *p* \< 0.001) and body weight (WMD − 1.22 kg; *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}; ESM Fig. S3).

Initial combinations of SGLT2 inhibitors plus metformin led to significant decreases in HbA1c (WMD, − 0.47%, *p* \< 0.001), FPG (WMD, − 1.38 mmol/l, *p* \< 0.001) and body weight (WMD, − 2.00 kg, *p* \< 0.001) when compared with metformin monotherapy. Initial combinations of SGLT2 inhibitors plus metformin also led to significant decreases in HbA1c (WMD − 0.64%; *p* \< 0.001) and FPG (WMD − 0.83 mmol/l; *p* \< 0.001) levels and body weight (WMD − 0.66 kg; *p* \< 0.001) when compared to SGLT2 inhibitor monotherapy (Table [2](#Tab2){ref-type="table"}; ESM Fig. S3).

Compared with TZD monotherapy, initial combinations of DPP-4 inhibitors plus TZD exhibited significant decreases in the levels of HbA1c (WMD − 0.54%; *p* \< 0.001), FPG (WMD − 0.89 mmol/l; *p* \< 0.001) and PPG (WMD − 1.97 mmol/l; *p* \< 0.001) but increased body weight significantly (WMD 0.96 kg; *p* \< 0.001). Compared with DPP-4 inhibitor monotherapy, initial combinations of DPP-4 inhibitors plus TZD resulted in significant decreases in HbA1c (WMD − 0.62%; *p* \< 0.001) and FPG (WMD − 1.41 mmol/l; *p* \< 0.001) levels but significant increases in body weight (WMD 3.51 kg; *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}; ESM Fig. S3).

Meta-regression analysis indicated that compared with monotherapy, the decrease in HbA1c level from baseline at initial combination therapy in each treatment group was not associated with the baseline HbA1c level adjusted by age, gender, and baseline BMI. However, when all data were pooled together, adjusted by age, gender and baseline BMI, HbA1c changes from baseline in the total combination therapy corrected by monotherapy was associated with baseline HbA1c level (coefficient − 2.98, 95% CI − 5.32 to − 0.63; *p* = 0.014) (ESM Table S4).

Adverse Effects of Initial Combination Therapy {#Sec9}
----------------------------------------------

Compared with metformin monotherapy, initial combinations of DPP-4 inhibitors plus metformin did not increase the risks of hypoglycemia, serious adverse effects (SAEs) or gastrointestinal (GI) side effects or the risk of discontinuation due to adverse effects (AEs) or drug-related AEs. When compared with DPP-4 inhibitor monotherapy, initial combinations of DPP-4 inhibitors plus metformin significantly increased the risks of hypoglycemia (RR 1.84; *p* = 0.007) and GI side effects (RR 2.19; *p* \< 0.001) and the risk of drug-related AEs (RR, 1.73, *p* \< 0.001).

Compared with metformin monotherapy, initial combinations of SU/glinides plus metformin significantly increased the risk of hypoglycemia (RR 8.91; *p* = 0.02). Compared with SU/glinide monotherapy, initial combinations of SU/glinides plus metformin significantly decreased the risk of hypoglycemia (RR 0.63; *p* \< 0.001) but increased the risk of GI side effects (RR 1.42; *p* = 0.01).

Compared with metformin monotherapy, initial combinations of TZDs and metformin significantly increased the risk of hypoglycemia (RR 1.60; *p* = 0.03). Compared with TZD monotherapy, initial combinations of TZDs plus metformin did not increase the risks of any AEs.

Compared with metformin monotherapy, initial combinations of SGLT2 inhibitors and metformin significantly increased the risk of drug-related AEs (RR 1.45; *p* = 0.004). Compared with SGLT2 inhibitor monotherapy, initial combinations of SGLT2 inhibitors plus metformin significantly increased the risks of hypoglycemia (RR 2.23; *p* = 0.02) and GI side effects (RR 1.99; *p* = 0.002).

Compared with DPP-4 inhibitor monotherapy or TZD monotherapy, initial combinations of DPP-4 inhibitors plus TZD did not increase any risk of AEs (Table [3](#Tab3){ref-type="table"}).Table 3Comparisons of initial combination therapy versus monotherapy in terms of the risks of hypoglycemia and other adverse effectsComparison groupNo. of patientsRelative risk95% CI*p* value*I*^2^ (%)95% CI of *I*^2^DPP-4 inhibitors + metformin vs. DPP-4 inhibitors AE1967/19511.070.94, 1.220.290− 0.24, 0.24 Drug-related AE1514/14891.731.39, 2.16\< 0.0012− 0.25, 0.29 Hypoglycemia1824/18231.841.19, 2.850.007270.02, 0.52 GI adverse effects1584/15912.191.48, 3.23\< 0.001620.33, 0.91 SAE1742/17460.700.45, 1.080.11420.15, 0.69 Discontinuation due to AE1584/15910.770.48, 1.240.2912− 0.17, 0.41DPP-4 inhibitors + metformin vs. metformin AE3379/33750.920.83, 1.010.090− 0.19, 0.19 Drug-related AE2926/29200.970.84, 1.110.630− 0.20, 0.20 Hypoglycemia3379/33751.150.84, 1.550.3817− 0.02, 0.36 GI adverse effects2996/29890.910.80, 1.040.170− 0.21, 0.21 SAE3154/31500.710.50, 1.010.050− 0.20, 0.20 Discontinuation due to AE2996/29890.880.63, 1.220.440− 0.21, 0.21SU/glinide + metformin vs.metformin AE425/4291.260.90, 1.760.170− 0.68, 0.68 Hypoglycemia425/4298.911.46, 54.340.02760.08, 1.44 GI adverse effects425/4290.700.48, 1.010.0665− 0.03, 1.33 SAE------------ Discontinuation due to AE------------SU/glinide + metformin vs. SU/glinide AE425/4160.980.70, 1.370.920− 0.68, 0.68 Hypoglycemia425/4160.630.48, 0.82\< 0.001930.25, 1.61 GI adverse effects425/4161.421.08,1.880.0125− 0.43, 0.93 SAE------------ Discontinuation due to AE------------TZD +  metformin vs.metformin AE954/9701.060.88, 1.280.550− 0.49, 0.49 Hypoglycemia954/9701.601.05, 2.460.030− 0.49, 0.49 GI adverse effects954/9700.870.75, 1.010.070− 0.49, 0.49 SAE954/9700.980.65, 1.470.910− 0.49, 0.49 Discontinuation due to AE954/9701.060.72, 1.560.760− 0.49, 0.49TZD + metformin vs. TZD AE356/3481.310.97, 1.760.0884-- Hypoglycemia356/3481.530.80, 2.910.200-- GI adverse effects------------ SAE356/3480.870.32, 2.370.790-- Discontinuation due to AE------------SGLT2 inhibitors + metformin vs. metformin AE978/9741.190.99, 1.430.063− 0.37, 0.43 Drug-related AE978/9741.451.12, 1.870.0040− 0.40, 0.40 Hypoglycemia642/6461.370.64, 2.920.4217− 0.51, 0.85 GI adverse effects978/9740.720.40, 1.070.25730.33, 1.13 SAE978/9740.840.43, 1.650.620− 0.49, 0.49 Discontinuation due to AE978/9740.820.47, 1.410.460− 0.40, 0.40SGLT2 inhibitors + metformin vs. SGLT2 inhibitors AE1220/12361.160.99, 1.370.07520.12, 0.92 Drug-related AE1220/12361.130.90, 1.420.31680.28, 1.08 Hypoglycemia642/6462.231.13, 4.410.0227− 0.41, 0.95 GI adverse effects978/9891.991.39, 2.860.0020− 0.40, 0.40 SAE978/9890.620.33, 1.160.130− 0.40, 0.40 Discontinuation due to AE978/9890.830.48, 1.430.500− 0.40, 0.40DPP-4 inhibitors + TZD vs. TZD AE1154/11380.940.80, 1.120.500− 0.35, 0.35 Drug-related AE1265/11071.060.79, 1.410.700− 0.35, 0.35 Hypoglycemia1413/12681.080.77, 1.530.650− 0.31, 0.31 GI adverse effects1265/11070.860.56, 1.330.5025− 0.10, 0.60 SAE1170/11401.310.85, .2.010.220− 0.35, 0.35 Discontinuation due to AE1006/9770.800.47, 1.380.423− 0.37, 0.43DPP-4 inhibitors + TZD vs. DPP-4 inhibitors AE502/5041.090.85, 1.400.5045− 0.68, 0.68 Drug-related AE350/3541.400.92, 2.150.1217-- Hypoglycemia350/3540.840.46, 1.530.570-- GI adverse effects------------ SAE350/3541.310.66, 2.590.4478-- Discontinuation due to AE------------*AE* Adverse effect, *GI* gastrointestinal, *SAE* serious adverse effect

Subgroup Analysis and Sensitivity Analysis {#Sec10}
------------------------------------------

The data were further analyzed by stratification by the study time periods. Since most studies were conducted with a 24-week follow-up, therefore, subgroup analyses were made in those studies which reported on a 24-week period of outcomes. These studies showed similar comparison results between initial combination therapy and monotherapy (ESM Table S5). We also included and excluded the study with the longest study duration of 80 weeks \[[@CR31]\] for sensitivity analysis and found the results were all similar with the total ones. Moreover, there were several studies including both drug-naïve patients and patients previously on anti-hyperglycemia agents \[[@CR13], [@CR17], [@CR20], [@CR27], [@CR29], [@CR39], [@CR40]\], in which the percentage of drug-naïve patients ranged from 50 to 90% (ESM Table S3). We also conducted a sensitivity analysis and found similar results as those for the efficacy and safety evaluations.

Discussion {#Sec11}
==========

Montherapy is unlike to achieve glycemic targets in patients with a high baseline HbA1c level (≥ 9%) \[[@CR2]\], and in such cases the guidelines of the ADA/EASD recommend that the patient receive initial combination therapy \[[@CR2]\]. In terms of "high" baseline HbA1c level, the AACE recommends initial pharmacologic combination treatment in patients with a HbA1c level of \> 7.5% \[[@CR5]\], and the Canadian Diabetes Association recommends initial combination therapy in patients with a HbA1c level of \> 8.5% \[[@CR49]\]. Among all sets of guidelines, the justification for initiating combination therapy is that patient would be unlikely to reach the glycemic target with monotherapy. The results of our meta-analysis supports that rationale, with most initial combination therapies---compared with monotherapy---showing superior glucose control in type 2 diabetes patients with an initial HbA1c level of \> 7.5% at a similar risk of hypoglycemia.

As previously indicated \[[@CR50], [@CR51]\], there are a number of rationales for initial combination therapy in patients with type 2 diabetes. First, such therapy may lead to early robust lowering of HbA1c levels; as demonstrated by our meta-analysis, most initial combination therapies showed superior glucose control compared to monotherapy. Second, initial combination therapy may avoid the clinical inertia associated with a stepwise approach to therapy. The authors of one study suggested that the time to receive additional anti-hyperglycemic medication exceeded 1 year for patients who failed metformin monotherapy and that this delay was associated with clinical inertia \[[@CR52]\]. Consequently, initial combination therapy may one of the best options to directly address the causes of clinical inertia \[[@CR52]\]. Third, initial combination therapy may improve ß-cell function \[[@CR50], [@CR51]\]. However, this finding was not clearly evident in our meta-analysis due to the lack of data. Fourth, the complementary mechanisms of action provided by initial combination therapy may require comparatively lower doses of individual agents and therefore may cause fewer AEs. This benefit was indicated by the results of our meta-analysis which showed that most initial combination therapies exhibited better glucose control with comparable risks of hypoglycemia, SAEs, discontinuation due to AEs and GI side effects. Fifth, initial combination therapy may avoid the long-term consequences of metabolic memory, as the initial use of combination therapy could lead to greater HbA1c reduction, enabling more individuals to achieve their glycemic goals while avoiding AEs stemming from multiple metabolic defects \[[@CR51], [@CR53], [@CR54]\]. However, this latter potential benefit may not be concluded from the present meta-analysis because most of the studies included were of short-term duration.

The evidence is compelling that type 2 diabetes is a progressive, physiologically and genetically complex heterogeneous disease. Achieving glycemic control is necessary to prevent or delay the progression of vascular complications. As current treatment approaches do not adequately acknowledge the complexity of diabetes, a compelling case may be made for combination treatment \[[@CR51]\]. Initial combination therapy may be required to address the complex pathophysiology of type 2 diabetes, which includes improving insulin secretion and insulin sensitivity, inhibiting hepatic glucose production and addressing delayed gastric emptying or glucose absorption, while focusing on satiety and renal glucosuria. Among the mechanisms of hypoglycemic agents \[[@CR55]\], metformin inhibits hepatic gluconeogenesis and improves peripheral insulin sensitivity, SUs/glinides stimulate insulin secretion by β-cells, DPP-4 inhibitors stimulate insulin secretion and suppress glucagon secretion, SGLT2 inhibitors reduce renal glucose reabsorption and induce urinary glucose excretion, TZDs activate peroxisome proliferator-activated receptor gamma (PPAR-γ) and increase insulin sensitivity. Therefore, choices for initial combinations of the above agents should also be supported by the pathophysiology of type 2 diabetes.

However, a number of unresolved issues associated with initial combination therapy in type 2 diabetes patients remain. One of these is whether initial combination therapy improve adherence. To date, there is no evidence suggesting that initial combination therapy versus monotherapy or sequential titration therapy would result in a greater adherence of patients to the therapeutic regimen. However, published studies do show that the more complex the drug regimen, the lower the adherence to that regimen \[[@CR56]\]. In our meta-analysis, we did not collect any data on a possible improvement in adherence. Another issue is cost; is initial combination therapy less costly? The relatively high cost of including novel agents, such as DPP-4 inhibitors or SGLT2 inhibitors, in an initial combination with metformin remains a significant barrier to their use in many regions of the world \[[@CR51]\]. Several studies have estimated the cost-effectiveness associated with monotherapy compared to combination therapy with oral anti-diabetes agents, but a number of these these were derived from non-RCT data and had multiple confounders \[[@CR57], [@CR58]\]. Moreover, the authors of another study indicated that it was difficult to quantify the cost-effectiveness of softer outcomes such as fewer hypoglycemic events or improved quality of life \[[@CR59]\]. We did not collect any data on the costs of initial combination therapy in our meta-analysis, but there are other economic models which could be used to answer this question. Moreover, the association between initial combination therapy and cardiovascular risk has not been fully examined in the literature. Gaps still exist in the evidence on treatment paradigms utilizing sequential versus initial combination therapy. Therefore, carefully designed, pragmatic, prospective real-world studies to assess the clinical effectiveness of initial combinations versus sequential treatment in patients with newly diagnosed or poorly controlled type 2 diabetes should be performed to provide more evidence.

There were several limitations to our meta-analysis. First, data from the separate studies covered different durations of the study. As previously indicated, RRs are sensitive to the length of the follow-up; consequently, the pooling of results from studies with different durations of follow-up might lead to an artificial heterogeneity and discrepancy in the meta-analyses \[[@CR60]\]. We therefore explored the outcomes in subgroup analyses by pooling all of the studies with a study period of 24 weeks to conduct a sensitivity analysis, which showed similar results with the total results. Second, the definitions of treatment-naïve patients varied depending on the protocols of the trials included in our meta-analysis, and these differences may also be associated with the high heterogeneity of this study and also lower the ability of the authors of this study to propose solid conclusions. Therefore, we also conducted a sensitivity analysis to minimize the bias and found the similar results to the efficacy and safety evaluations. The large differences in the number of studies for several combinations is another limitation. For those treatment groups with only one trial included \[[@CR41]--[@CR48]\], no further meta-analysis was done for evaluation purposes. Another problem may be the variations in dosages used in the different studies. Therefore, the standard doses recommended and approved in the clinical practice were used in this meta-analysis to minimize the bias. Since baseline characteristics were variable across studies, we used the random-effects model for analysis when the level of heterogeneity was high. Given these factors, we suggest that our results be interpreted cautiously.

Conclusions {#Sec12}
===========

In conclusion, compared with monotherapy, all initial combination therapies resulted in significantly reduced HbA1c levels in treatment-naïve type 2 diabetes patients. Compared with metformin monotherapy, the initial combination therapies of DPP-4 inhibitors plus metformin and SGLT2 inhibitors plus metformin exhibited similar risks of hypoglycemia, but the initial combination therapies of SU plus metformin and TZD plus metformin exhibited higher risks of hypoglycemia.
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